ClinicalTrials.gg
RecruitingNCT06865417GalapeducaUpdated Oct 20, 2026

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

A Phase 3 interventional study of Filgotinib in Ulcerative Colitis, sponsored by Alfasigma S.p.A.. Recruiting at 46 sites in 13 countries. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Alfasigma S.p.A. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 20, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Colitis, Ulcerative with a site in Italy — 48 open to participants now, 77 under way, 27 of them phase 3. Colitis, Ulcerative · Italy.

Planned enrollment
130th of 175
80 · median 182
Started
2025
with 18 others
Phase 3
65 of 209
11 open now
Primary completion
2028-06
later than 61 of 76 live
Registered
175th of 209
by date

Among the 209 studies in Colitis, Ulcerative with a site in Italy, this one is the 130th largest by planned enrollment of the 175 interventional ones that give a count, is one of 19 that started in 2025, is one of 65 in phase 3, reaches primary completion later than 61 of the 76 other live ones, and was the 175th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

48 of the 209 studies in Colitis, Ulcerative with a site in Italy are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Colitis, Ulcerative with a site in Italy, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of filgotinib as a treatment for UC in children and adolescents aged from 8 to less than 18 years.

Approximately 80 subjects from 8 to \<18 years of age with moderately to severely active UC, including a minimum of 8 subjects from 8 to \<12 years of age, will be enrolled in this study.

During the study, eligible subjects will take the investigational product (IP) on-site at Week 4, Week 10, and Week 22 (in the morning; with or without food). On all other days, subjects will take IP at home (in the morning; with or without food).

Subjects who do not achieve mMCS remission and/or MCS response at Week 10 will continue with induction treatment until Week 22. Subjects who do not achieve PUCAI remission at Week 22 will be permanently discontinued from the study.

Subjects will all receive a filgotinib dose targeting the same systemic exposure as that observed in adults with UC treated with 200 mg q.d.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have a minimum body weight (BW) of 15 kg.
  • Subject:

    • has documented diagnosis of UC with a minimum duration of 3 months,
    • has mMCS of 5 to 9, and an MCS endoscopic score >=2, rectal bleeding >=1, and stool frequency >=1,
    • has had an inadequate response, loss of response, intolerance, or has medical to , , and/or biologic therapy. This includes subjects who depend on corticosteroids to control their symptoms and who experience worsening of their disease when attempting to wean off corticosteroids.

Exclusion criteria

Exclusion Criteria:

  • Subject has a diagnosis of inflammatory bowel disease -unclassified or indeterminate colitis, isolated proctitis, or toxic megacolon.
  • Subject has an active infection.
  • Subject with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement).
  • Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, herpes zoster, or atypical mycobacteria).
  • Subject has a history of colectomy or extensive small bowel resection.
  • Subject with psychological or cognitive difficulties that might interfere with study participation.
  • Subject has any previous exposure to a Janus kinase inhibitor or medication with a similar mode of action (e.g. tofacitinib, baricitinib, upadacitinib).
  • Female subject is pregnant or breast feeding or intending to become pregnant or breastfeed during the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Filgotinib

    Filgotinib

    Drug: Filgotinib

Interventions

  • IP will be provided as commercially developed film-coated tablets (100 and 200 mg strength) or reduced-strength (65 mg) age-appropriate film-coated tablets for use in pediatric subjects aged at least 8 years and needs to be taken orally q.d. at approximately the same time every morning (with or without food).

06

What researchers measure

Primary outcomes

  1. Efficacy of filgotinib in induction of remission and maintenance of effect in pediatric subjects with ulcerative colitis (UC)

    Proportion of subjects achieving clinical remission based on modified Mayo Clinical Score (mMCS)

    Time frame: Week 10

  2. subjects with ulcerative colitis (UC)

    Proportion of subjects achieving clinical remission based on mMCS

    Time frame: Week 58

Secondary outcomes

  1. Safety and tolerability of filgotinib in pediatric subjects with UC

    Incidence of treatment-emergent adverse events (TEAEs), adverse events of interest, and laboratory abnormalities through follow-up

    Time frame: Week 62

  2. Safety and tolerability of filgotinib in pediatric subjects with UC

    Change from baseline in body mass index (BMI)

    Time frame: Week 58

  3. Safety and tolerability of filgotinib in pediatric subjects with U

    Change from baseline in height velocity

    Time frame: Week 58

07

Study locations

44 of 46 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2028, 33 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 33 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 7, 2025
StartActual
Sep 29, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola · Brussels, BelgiumNot yet recruiting→Recruiting
  • Centre Hospitalier Regional De La Citadelle · Liège, BelgiumNot yet recruiting→Recruiting
  • Chelsea and Westminster Hospital · London, United KingdomNot yet recruiting→Recruiting
Show 1 removed
  • The Newcastle upon Tyne Hospital FT · Newcastle, United Kingdom
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    1 site removed. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola · Brussels, BelgiumNot yet recruiting→Recruiting
    • Centre Hospitalier Regional De La Citadelle · Liège, BelgiumNot yet recruiting→Recruiting
    • Chelsea and Westminster Hospital · London, United KingdomNot yet recruiting→Recruiting
    Show 1 removed
    • The Newcastle upon Tyne Hospital FT · Newcastle, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06865417
Lead sponsor
Alfasigma S.p.A.
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Sep 29, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Vincenzo Teneggi, MD
Contact
vincenzo.teneggi@external.alfasigma.com
00800 7878 1345
Alexandra Mangili, MD
Contact
alexandra.mangili@alfasigma.com
+041 795865622

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion